Safety of biological therapies: New data from BIOBADASER;Seguridad de las terapias biológicas: nuevos datos de BIOBADASER

Reumatologia Clinica

Volumn 6, Issue SUPPL. 3, 2010, Pages

  Rodríguez Lozano, Carlos ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

BIOBADASER; Biological therapy; Registry; Safety

Indexed keywords

BIOLOGICAL FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOLOGICAL THERAPY; CANCER RISK; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DEMYELINATING DISEASE; HUMAN; INFECTION RISK; LONG TERM EXPOSURE; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; PATIENT SAFETY; PSORIASIS; REGISTER; RISK REDUCTION; SIDE EFFECT; SPAIN; ABNORMALITIES, DRUG-INDUCED; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASE; CHEMICALLY INDUCED; DISEASE PREDISPOSITION; DRUG ERUPTIONS; FEMALE; INFECTION; MALE; NEOPLASM; PREGNANCY; STATISTICS AND NUMERICAL DATA;

ABNORMALITIES, DRUG-INDUCED; AUTOIMMUNE DISEASES; BIOLOGICAL THERAPY; DEMYELINATING DISEASES; DISEASE SUSCEPTIBILITY; DRUG ERUPTIONS; FEMALE; HUMANS; INFECTION; MALE; META-ANALYSIS AS TOPIC; NEOPLASMS; OBSERVATIONAL STUDY AS TOPIC; PREGNANCY; PSORIASIS; REGISTRIES; SPAIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952900117     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2010.11.009     Document Type: Article

References (22)

1. Comité Científico de BIOBADASER. BIOBADASER: Registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas. Rev Esp Reumatol. 2002;29:292-99.
2. Dixon W.G., Carmona L., Finckh A., Hetland M.L., Kvien T.K., Landewe R., et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis. 2010, 69:1596-1602.
3. García-Doval I., Pérez-Zafrilla B., Descalzo M.A., Roselló R., Hernández M.V., Gómez-Reino J.J., et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010, 69:1751-1755. BIOBADASER 2.0 Study Group.
4. Peña-Sagredo J.L., Hernández M.V., Fernandez-Llanio N., Giménez-Ubeda E., Muñoz-Fernandez S., Ortiz A., et al. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol. 2008, 26:854-859. for the Biobadaser group.
5. Peña-Sagredo J.L., Fariñas M.C., Perez-Zafrilla B., Cruz-Valenciano A., Crespo M., Joven-Ibañez B., et al. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy. Clin Exp Rheumatol. 2009, 27:920-925. for the BIOBADASER and EMECAR Groups.
6. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003, 48:2122-2127. on behalf of the BIOBADASER Group.
7. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., Montero D., Pascual-Gomez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005, 52:1766-1772.
8. Gomez-Reino J.J., Carmona L., Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007, 57:756-761.
9. Carmona L., Descalzo M.A., Ruiz-Montesinos D., Manero-Ruiz F.J., Perez-Pampin E., Gomez-Reino J.J. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology (Oxford). 2011, 50:85-92. on behalf of the BIOBADASER 2.0 Study Group.
10. Jacobsson L., Turesson C., Nilsson J.A., Petersson I., Lindqvist E., Saxne T., et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2007, 66:670-675.
11. Lunt M., Watson K.D., Dixon W.G. Symmons D and Hyrich K on behalf of the BSR Biologics Register No evidence of association between anti-TNF treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis & Rheumatism 2010, 62:3145-3153. The BSRBR Control Centre Consortium.
12. Carmona L., Descalzo M.A., Perez-Pampin E., Ruiz-Montesinos D., Erra A., Cobo T., et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis. 2007, 66:880-885. BIOBADASER and EMECAR Groups.
13. Pérez-Zafrilla B., Descalzo M.A., Carmona L. Reacciones adversas relacionadas con la administración de inhibidores del TNF. Análisis de un registro de terapias biológicas. Reumatol Clin. 2008, 4:90-95. Grupo de Estudio BIOBADASER.
14. Harrison M.J., Dixon W.G., Watson K.D., King Y., Groves R., Hyrich K.L., et al. British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor a therapy: results from the British Society for Rheumatology Biologics Register Ann Rheum Dis. 2009, 68:209-215.
15. Collamer A.N., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010, 40:233-240.
16. Bernatsky S., Renoux C., Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis. 2010, 69:1691-1693.
17. Fernández-Espartero M.C., Pérez-Zafrilla B., Naranjo A., Esteban C., Ortiz A.M., Gómez-Reino J.J., et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. Semin Arthritis Rheum. 2010, 40:330-337. the BIOBADASER Study Group.
18. Listing J., Strangfeld A., Kekow J., Schneider M., Kapelle A., Wassenberg S., Zink A. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis Rheum. 2008, 58:667-677.
19. Dixon W.G., Watson K.D., Lunt M., Hyrich K.L., Silman A.J., et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007, 56:2905-2912. British Society for Rheumatology Biologics Register Control Centre Consortium, on behalf of the British Society for Rheumatology Biologics Register.
20. Khasnis A.A., Calabrese L.H. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum. 2010, 40:147-163.
21. Pollono E.N., López-Olivo M.A., López J.A., Suárez-Almanzor M.E. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol. 2010, 29:947-955.
22. Vinet E., Pineau C., Gordon C., Clarke A.E., Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis & Rheumatism (Arthritis Care & Research) 2009, 61:587-592.